FORM 4

obligations may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

washington, L	J.C.	20549	
---------------	------	-------	--

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Tu Thomas						2. Issuer Name and Ticker or Trading Symbol Inari Medical, Inc. [ NARI ]								(Check	all appli Directo	onship of Reporting all applicable) Director Officer (give title		son(s) to Iss 10% Ov Other (s	wner	
	(Fi ARI MEDIC ER, SUITE	AL, INC.	(Middle)	)		3. Date of Earliest Transaction (Month/Day/Year) 08/27/2021							X Officer (give title Other below) below  Chief Medical Officer					Specify		
(Street) IRVINE (City)	C.	ate)	92618 (Zip)		-	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line) X						
		Tab	le I - N	Non-Deri	vative	Sec	uriti	ies A	cquire	ed, D	isposed o	of, or B	enefi	cially						
		2. Transact Date (Month/Day	te onth/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code ( 8)		ction Disposed Of (D		Acquired (A) or (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price		Transac	nsaction(s) str. 3 and 4)			(Instr. 4)			
Common	Common Stock 08/27/2		021	1		M		5,000	A	\$0	\$0.457		53,852		D					
Common	ommon Stock 08/27/20		021	<u>.</u>		S <sup>(1)</sup>		1,900	D	\$79.7	\$79.7532 <sup>(2)</sup>		51,952		D					
Common Stock 08/27/20		021	.1		S <sup>(1)</sup>		1,797	D	\$81.8683(3)		50,155			D						
Common Stock 08/27/20		021	21		<b>S</b> <sup>(1)</sup>		1,303	D	\$82.7979(4)		48,852			D						
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	eemed tion Date, n/Day/Year)	4. Transa Code ( 8)		5. Number 6. Date E Expiration		S. Date Exercisable and Expiration Date Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Secul (Instr. 3 and 4)		rity	Price of erivative ecurity estr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
			Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	or Num of Sha	ber								
Stock Option	\$0.457	08/27/2021			M			5,000	(5	5)	04/23/2029	Commo	<sup>n</sup> 5,0	00	\$0.00	225,58	4	D		

## **Explanation of Responses:**

- $1. \ The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2020.$
- 2. This transaction was executed in multiple trades at prices ranging from \$79.65 to \$80.34. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 3. This transaction was executed in multiple trades at prices ranging from \$81.23 to \$82.20. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 4. This transaction was executed in multiple trades at prices ranging from \$82.26 to \$83.18 The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- 5. Option vested with respected with 25% of the underline shares on April 30, 2020 and vest with respect to the remaining shares in 36 equal monthly installment there after.

## Remarks:

/s/ Angela Ahmad, attorney-infact for Thomas Tu

08/30/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.